During the presentation of the late-breaking abstract on the PEACE-1 study, Dr. Alberto Bossi, a radiation oncologist at Gustave Roussy in Villejuif, Paris, thoroughly discussed the study’s results.
The focus was on the impact of prostate irradiation in men with de novo, low volume, metastatic, castration-sensitive prostate cancer who received intensified systemic treatment. Dr. Bossi also discussed the potential of a digital pathology-based biomarker, derived from AI, to predict the benefit of long-term androgen deprivation therapy with radiotherapy for men with localized high-risk prostate cancer. Finally, Dr. Bossi analyzed individual patient data from the ICECAP collaborative, evaluating the prognostic impact of PSA nadir after completing radiotherapy for localized prostate cancer.
With the educational support of:
